Could a nasal insulin spray rewire the brain in psychosis?
NCT ID NCT07252752
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study investigates how insulin delivered through the nose changes dopamine signaling and energy use in the brains of people with first-episode psychosis. Researchers will compare brain scans and chemical levels in 46 participants (patients and healthy volunteers) after receiving insulin or a placebo. The goal is to understand the overlap between metabolic and psychiatric symptoms, not to treat the condition directly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
intranasal insulin
What this could lead to
If successful, this could reveal a link between insulin and dopamine in psychosis, pointing toward new treatment targets for schizophrenia.
What could go wrong
This is an early, small imaging study (46 people) that measures brain activity, not symptoms. It may not lead to any direct treatment or benefit for patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Medical University of Vienna
Vienna, 1090, Austria
Contact Phone: •••-•••-•••• Email: •••••@•••••